Navigate Up
Sign In


«Digital Health Care» was one of the topics of the 11th congress «Trendtage Gesundheit Luzern» on 18 and 19 March. The opportunities offered by digitalized data processing and the risks it may bring was debated in a panel discussion, in which Alexander Roediger, Director of European Union Affairs at Merck, was participating. MSD has been supporting the Trendtage Gesundheit Luzern for several years and since 2013 as a main partner.
Read more.

The Health Literacy Alliance conferred the health literacy prize of a total of 19,000 Swiss francs in Lucerne on 29 January 2015. This alliance supports projects that promote in an innovative way the knowledge and ability to behave healthy. The Alliance Health Literacy was established by Public Health Switzerland, Health Promotion Switzerland, the Careum Foundation, the Swiss Medical Association FMH and Merck Sharp & Dohme (MSD) 2010. Read more.

At the annual American Heart Association (AHA) Congress the results of the cholesterol study IMPROVE-IT were presented, confirming the relevance of additionally lowering cholesterol with patients who have an increased risk for additional myocardial infarction or stroke.
Read more.


​MSD in Switzerland

MSD is one of the world's leading healthcare companies, with its headquarters in the USA (Merck & Co., Inc.). In Switzerland, MSD is one of the most important pharmaceutical research companies. From our base at Lucerne we serve the Swiss healthcare market and support more than 70 subsidiaries across Europe, Canada, the Middle East, Africa, Brazil, India, and China. Welcome to MSD.

MSD as an employer 
To achieve our ambitious goals, we need the best possible specialist staff and highly committed employees. We offer various positions in a wide range of business areas like for example within our local and international sales organizations, research & development, manufacturing, and within the core departments of our global business located in Lucerne.
Find out more​

​The Antibiotics Challenge  

For more than 70 years, MSD has contributed to the discovery and development of novel medicines to combat infectious diseases. The combination with the bio-pharmaceutical company Cubist in January 2015 is an important milestone in this respect to intensify research in view of an increasing resistance against antibiotics – one of the biggest global health challenges - and develop innovative medicines for patients with potentially life-threatening infections diseases caused by bacteria. Cubist’s deep expertise and compelling portfolio and pipeline complement our broad portfolio of Hospital Acute Care. This will help advance a pipeline of candidates that hold the potential for making a meaningful difference in the lives of patients around the world.

General Remark:
Please be aware of the fact that each time when using one of the links in this website, you are leaving the MSD Merck Sharp & Dohme AG, Switzerland (MSD), website and thus our sphere of responsibility. The linked Internet pages have their own terms of use and may be subject to different laws and standards.